Abstract Library

#3747 Characteristics of Pancreatic Neuroendocrine Tumors (PNET) patients treated with Peptide Receptor Radionuclide Therapy (PRRT) in two Canadian centers – A real-world evidence study

Introduction: PRRT is a standard practice for treatment of metastatic midgut neuroendocrine tumors. PNET patients who progressed on prior therapy are also considered for PRRT if accessible via special access.

Conference:

Presenting Author: Tsvetkova E

Authors: Tsvetkova E, Welch S, Laidley D, Sachdeva R, Goodwin R,

Keywords: Pancreatic Neuroendocrine Tumor, Peptide Receptor Radionuclide Therapy, Real World Experience,

#3441 Management of type-I gastric neuroendocrine neoplasms: A single center’s real world experience

Introduction: Currently, the optimal management of Type-1 gastric neuroendocrine neoplasms (T1gNENs) remains an active issue. The best endoscopic approach still needs to be defined.

Conference:

Presenting Author: Rinzivillo M

Authors: Rinzivillo M, Cazzato M, Esposito G, Lorenzi C, Pilozzi E,

Keywords: gastric neuroendocrine tumor, endoscopic resection,

#3301 Telotristat in the management of carcinoid diarrhoea - Real world experience of patients from an ENETS Centre of Excellence in neuroendocrine tumors

Introduction: Carcinoid syndrome occurs in 20% patients, presenting with flushing, abdominal pain, diarrhoea, and wheeze. The standard of care for carcinoid syndrome is somatostatin analogues (SSAs) with add-on Creon, codeine and loperamide therapy. Nonetheless, half of patients experience debilitating diarrhoea. Telotristat-ethyl is a peripheral tryptophan-hydroxylase inhibitor approved for treatment of diarrhoea, supported by Phase-3 clinical trials.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Cianci N

Authors: Khanna A, Cianci N, Shah H, Chauhan J, Pipe M,

Keywords: Telotristat, carcinoid syndrome, somatostatin analogues, neuroendocrine tumor,